Chronic l-α-acetylmethadol (LAAM) in rhesus monkeys: Tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 168-178

  Brandt, Michael R ^a   France, Charles P ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ACETYLMETHADOL; ALFENTANIL; DYNORPHIN; MORPHINE DERIVATIVE; NALBUPHINE; NALTREXONE; OPIATE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CROSS TOLERANCE; DOSE RESPONSE; DRUG ABUSE; DRUG TOLERANCE; MONKEY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; DRUG TOLERANCE; DYNORPHINS; FEMALE; KETAMINE; MACACA MULATTA; MALE; METHADYL ACETATE; NALBUPHINE; NALTREXONE; NARCOTICS; RESPIRATION;

EID: 0033918476     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bertalmio AJ, Medzihradsky F, Winger G and Woods JH (1992) Differential influence of N-dealkylation on the stimulus properties of some opioid agonists. J Pharmacol Exp Ther 261:278-284.
2. Blasig J, Herz A, Reinhold K and Zieglgansberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia (Bert) 33:19-38.
3. Brandt MR, Cabansag SR and France CP (1997) Discriminative stimulus effects of l-α-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 282:574-584.
4. Brandt MR and France CP (1998) Chronic l-alpha acetylmethadol in rhesus monkeys: Discriminative stimulus and other behavioral measures of dependence and withdrawal. J Pharmacol Exp Ther 287:1029-1037.
5. Butelman ER, France CP and Woods JH (1995) Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 275:374-380.
6. Butelman ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zernig G and Woods JH (1998) Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. J Pharmacol Exp Ther 285: 595-601.
7. Butelman ER, Negus SS, Ai Y, de Costa BR and Woods JH (1993) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267:1269-1276.
8. Craft RM and Dykstra LA (1992) Agonist and antagonist activity of kappa opioid in the squirrel monkey: I. Antinociception and urine output. J Pharmacol Exp Ther 260:327-333.
9. Craft RM, Picker MJ and Dykstra LA (1989) Differential cross-tolerance to opioid agonists in morphine-tolerant pigeons responding under a schedule of food presentation. J Pharmacol Exp Ther 249:386-393.
10. De Leon-Casasola OA, Myers DP, Donaparthi S, Bacon DR, Peppriell J, Rempel J and Lema MJ (1993) A comparison of postoperative epidural analgesia between patients with chronic cancer taking high doses of oral opioids versus opioid-naive patients. Anesth Analg 76:302-307.
11. Dosaka-Akita K, Tortella FC, Holaday JW and Long JB (1993) The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonist in conscious rats. J Pharmacol Exp Ther 264:631-637.
12. 6 glioma cell line expressing the μ opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
13. Finkle BS, Jennison TA, Chinn DM, Ling W and Holmes ED (1982) Plasma and urine disposition of l-α-acetylmethadol and its principal metabolites in man. J Anal Toxicol 6:100-105.
14. France CP, Medzihradsky F and Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268:47-58.
15. Gerak LR, Butelman ER, Woods JH and France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993-999.
16. Gmerek DE, Dykstra LA and Woods JH (1987) Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242: 428-436.
17. Goldberg SR (1976) Conditioned behavioral and physiological changes associated with injections of a narcotic antagonist in morphine-dependent monkeys. Pavlov J Biol Sci 11:203-221.
18. Gourlay GK, Cherry DA and Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297-312.
19. Henderson GL, Weinberg JA, Hargreaves WA, Lau DHM, Tyler J and Baker B (1977) Accumulation of l-α-acetylmethadol [LAAM] and active metabolites in plasma following chronic administration. J Anal Toxicol 1:1-5.
20. Holtzman SG (1979) Discriminative stimulus properties of levo-alpha-acetylmethadol and its metabolites. Pharmacol Biochem Behav 10:565-568.
21. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC and Hughes J (1990) CI-977, a novel and selective agonist for the Κ-opioid receptor. Br J Pharmacol 101:183-189.
22. Jasinski DR, Johnson RE and Kocker TR (1985) Clonidine in morphine withdrawal. Arch Gen Psychiatry 42:1063-1066.
23. Kanof PD, Handelsman L, Aronson MJ, Ness R, Cochrane KJ and Rubinstein KL (1992) Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther 260:355-363.
24. Kreek MJ (1992) Rationale for maintenance pharmacotherapy of opiate dependence, in Addictive States (O'Brien CP and Jaffe JH eds) pp 205-230, Raven Press New York.
25. Levine R, Zaks A, Fink M and Freedman AM (1973) Levomethadyl acetate: Prolonged duration of opioid effects, including cross tolerance to heroin, in man. J Am Med Assoc 226:316-318.
26. Marks CE and Goldring RM (1973) Chronic hypercapnia during methadone maintenance. Am Rev Respir Dis 108:1088-1093.
27. Martin WR and Jasinski DR (1969) Physiological parameters of morphine dependence in man: Tolerance, early abstinence, protracted abstinence. J Psychiatr Res 7:9-17.
28. Martin WR, Jasinski DR, Sapira JD, Flanary HG, Kelly OA, Thompson AK and Logan CR (1968) The respiratory effects of morphine during a cycle of dependence. J Pharmacol Exp Ther 62:182-189.
29. McGilliard KL and Takemori AE (1978) Alterations in the antagonism by naloxone of morphine-induced respiratory depression and analgesia after morphine pretreatment. J Pharmacol Exp Ther 207:884-891.
30. Paronis CA and Holtzman SG (1992) Development of tolerance to the analgesic activity of mu-agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262:1-9.
31. Paronis CA and Woods JH (1997a) Ventilation in morphine-maintained rhesus monkeys. I: Effects of naltrexone and abstinence-associated withdrawal. J Pharmacol Exp Ther 282:348-354.
32. Paronis CA and Woods JH (1997b) Ventilation in morphine-maintained rhesus monkeys. II: Tolerance to the antinociceptive but not the ventilatory effects of morphine. J Pharmacol Exp Ther 282:355-362.
33. Pfeifer BL, Sernaker HL, Ter Horst UM and Forges SW (1989) Cross-tolerance between systemic and epidural morphine in cancer patients. Pain 39:181-187.
34. Pitts RC and Dykstra LA (1994) Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys. J Pharmacol Exp Ther 271: 1501-1508.
35. Portenoy RK and Foley KM (1986) Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 25:171-186.
36. Takemori AE, Loh HH and Lee NM (1992) Suppression by dynorphin A (1-13) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221:223-226.
37. Tulunay CF, Jen M-F, Chang J-K, Loh HH and Lee NM (1981) Possible regulatory role of dynorphin on morphine- and β-endorphin-induced analgesia. J Pharmacol Exp Ther 219:296-298.
38. VonVoigtlander PF, Lahti RA and Ludens JH (1983) U-50,488: A selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7-12.
39. Walker EA, Zernig G and Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273: 1345-1352.
40. Young AM, Kapitsopoulos G and Makhay MM (1991) Tolerance to morphine-like stimulus effects of mu opioid agonist. J Pharmacol Exp Ther 257:795-805.